BioSpace News Archive

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, intends to report operational highlights and financial results for the year ended December 31, 2019 on Thursday, February 20, 2020,

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2019.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its RiVax

FORMA Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the online publication of the structure-based design and discovery of its most advanced clinical asset, olutasidenib, in the Journal of Medicinal Chemistry

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2019 and provided financial expectations for 2020.

Incyte (Nasdaq:INCY) today reports 2019 fourth quarter and year-end financial results, announces 2020 guidance and provides a status update on the Company’s development portfolio.

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced the U.S. Food and Drug Administration (FDA) approval of the STIM onTrack™ mobile app version 2.1 for use with the Company’s bone growth stimulators.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), announced today that its fourth quarter and full year 2019 financial results will be released after the market closes on Thursday, February 20, 2020.

BD announced a new, $6 million contract with the Fleming Fund, a U.K. aid program that helps low- and middle-income countries around the world tackle antimicrobial resistance.

SCRUM-Japan aims to apply blood-based genomic insights to inform and accelerate the development of precision medicine approaches for patients with advanced cancers